Hatanaka Marcelo, Vessani Roberto M, Elias Isalina R, Morita Celso, Susanna Remo
Department of Opthalmology, University of São Paulo School of Medicine, São Paulo, Brazil.
J Ocul Pharmacol Ther. 2009 Feb;25(1):51-3. doi: 10.1089/jop.2007.0125.
The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT).
A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 +/- 9.2 (range, 48-85) years old.
A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 +/- 35.4 vs. 540.35 +/- 35.9 microm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 +/- 32.0 vs. 532.25 +/- 30.4 microm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 +/- 32.4 vs. 543.88 +/- 35.6 microm (P = 0.036).
Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
本研究旨在验证前列腺素类似物和前列腺酰胺对中央角膜厚度（CCT）的影响。
对接受前列腺素类似物（0.005%拉坦前列素或0.004%曲伏前列素）或前列腺酰胺（0.03%比马前列素）单药治疗8周的青光眼患者的CCT进行前瞻性分析。还评估了未使用任何眼部药物的对照组患者。使用市售超声角膜测厚仪进行CCT测量。本研究共纳入73例患者。平均年龄为68.5±9.2（范围48 - 85）岁。
除对照组（n = 21）外，所有组的CCT均出现统计学显著降低：0.03%比马前列素组（n = 21）：544.41±35.4对540.35±35.9微米（P = 0.039）；0.004%曲伏前列素组（n = 17）：538.47±32.0对532.25±30.4微米（P = 0.009）；0.005%拉坦前列素组（n = 14）：548.57±32.4对543.88±35.6微米（P = 0.036）。
前列腺素类似物和比马前列素局部治疗至少8周与CCT降低有关。
